Kadmon Investors and Media

Investors

Press Releases

Press Releases

Kadmon Announces 12 Month Data from Pivotal Trial of Belumosudil for cGVHD at the 62nd ASH Annual Meeting

- ORRs of 73% and 77% with Belumosudil 200 mg QD and 200 mg BID, Respectively - - cGVHD Key Opinion Leader Webcast Today at 2:15 p.m. Eastern Time ( 11:15 a.m. Pacific Time ) - NEW YORK, NY / ACCESSWIRE / December 6, 2020 /   Kadmon Holdings, Inc. (Nasdaq:KDMN) today announced 12-month data from... Read More

Kadmon Announces FDA Acceptance of NDA for Belumosudil in Patients With Chronic Graft-Versus-Host Disease

- FDA Grants Priority Review and Sets PDUFA Date of May 30, 2021 - - Application Being Evaluated Under FDA's Real-Time Oncology Review (RTOR) and Project Orbis Pilot Programs - NEW YORK, NY / ACCESSWIRE / November 30, 2020 /   Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced that the U.S.... Read More

Kadmon to Host Virtual Key Opinion Leader Event at the 62nd ASH Annual Meeting

NEW YORK, NY / ACCESSWIRE / November 24, 2020   /   Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced that the Company will host a virtual key opinion leader event on Sunday, December 6, 2020 at 11:15 a.m. PT ( 2:15 p.m. ET ) at the 62 nd   American Society of Hematology (ASH) Annual Meeting.... Read More

Kadmon to Present at Upcoming Investor Conferences

NEW YORK, NY / ACCESSWIRE / November 12, 2020 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced that Harlan W. Waksal , M.D., President and Chief Executive Officer, will present at the following virtual investor conferences: Jefferies Virtual London Healthcare Conference Date: Wednesday,... Read More

Kadmon Provides Business Update and Reports Third Quarter 2020 Financial Results

NEW YORK, NY / ACCESSWIRE / November 5, 2020 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today provided a business update and reported financial and operational results for the third quarter of 2020. "The submission of our belumosudil New Drug Application to the FDA represents a significant achievement... Read More

Kadmon to Present 12-Month Data from Pivotal Trial of Belumosudil for cGVHD at the 62nd ASH Annual Meeting

NEW YORK, NY / ACCESSWIRE / November 4, 2020 / Kadmon Holdings, Inc. (NASDAQ:KDMN) announced today that 12-month data from ROCKstar (KD025-213), the ongoing pivotal trial of belumosudil (KD025) for the treatment of chronic graft-versus-host disease (cGVHD), have been selected for oral presentation... Read More

Kadmon Announces Abstract Accepted for Presentation at the Society for Immunotherapy of Cancer's 35th Anniversary Annual Meeting

NEW YORK, NY / ACCESSWIRE / October 20, 2020 / Kadmon Holdings, Inc. (NYSE:KDMN) announced today it will present preclinical data on its anti-PD-1/IL-15 fusion protein in development for oncology indications, at the Society for Immunotherapy of Cancer's (SITC 2020) 35 th Anniversary Annual Meeting,... Read More

Kadmon to Transfer U.S. Stock Exchange Listing to Nasdaq

NEW YORK, NY / ACCESSWIRE / October 13, 2020 /   Kadmon Holdings, Inc. (NYSE:KDMN) announced today that it will voluntarily transfer its stock exchange listing from the New York Stock Exchange (NYSE) to the Nasdaq Global Select Market ("Nasdaq"). The Company will retain the "KDMN" ticker with... Read More

Kadmon Announces Submission of New Drug Application to the U.S. FDA for Belumosudil in Patients with Chronic Graft-Versus-Host Disease

Application Being Reviewed Under FDA's Real-Time Oncology Review (RTOR) Pilot Program NEW YORK, NY / ACCESSWIRE / September 30, 2020 /   Kadmon Holdings, Inc. (NYSE:KDMN) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for belumosudil... Read More

FDA Grants Orphan Drug Designation to Kadmon's Belumosudil for the Treatment of Systemic Sclerosis

NEW YORK, NY / ACCESSWIRE / September 8, 2020   /   Kadmon Holdings, Inc. (NYSE:KDMN) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to belumosudil (KD025), the Company's Rho-associated coiled-coil kinase 2 (ROCK2) inhibitor, for the treatment... Read More
Displaying 1 - 10 of 24